HC Wainwright Reiterates Buy Rating on Neumora Therapeutics
HC Wainwright maintains a buy rating for Neumora Therapeutics, setting a $7.00 price target.
Key Points
- On June 16, 2026, HC Wainwright reiterated its buy rating for Neumora Therapeutics, Inc. (NMRA) with a price target of $7.00.
- Shares of NMRA are trading around $0.91, with a market cap of approximately $289 million and a 52-week range of $0.716 to $3.65.
- Insiders including Fust Matthew and Ho Maykin recently bought shares, while analysts like Needham and Guggenheim have also set buy ratings.
On June 16, 2026, HC Wainwright reiterated its buy rating on Neumora Therapeutics, Inc. (NasdaqGS: NMRA), maintaining a price target of $7.00. This analysis comes as Neumora's shares are trading at around $0.91.
What Changed in HC Wainwright's Neumora Therapeutics Position
HC Wainwright's analyst Douglas Tsao continues to see potential in Neumora Therapeutics, maintaining a buy rating with a target price of $7.00. This suggests confidence in the company's future prospects, especially as it navigates its clinical trials.
Other Institutional Activity in Neumora Therapeutics
Several other institutional investors have also been active in Neumora Therapeutics. SIREN, L.L.C. increased its stake by 2,209,039 shares, bringing its total to 8,497,822 shares, valued at about $16.57 million. In contrast, SoftBank Group Corp. trimmed its holdings by 339,419 shares, ending with 6,090,301 shares worth approximately $11.88 million. Perceptive Advisors LLC initiated a new position with 5,104,097 shares valued at roughly $9.95 million. Meanwhile, Vanguard Capital Management LLC also started a new position, acquiring 3,891,893 shares valued at about $7.59 million.
Neumora Therapeutics Stock Snapshot
Shares of Neumora Therapeutics (NasdaqGS: NMRA) are currently trading near $0.91. The company has a market capitalization of approximately $289 million and a beta of 2.759, indicating higher volatility compared to the market. The stock's 52-week range spans from $0.716 to $3.65, with a 50-day moving average of $1.95 and a 200-day moving average of $2.20. Neumora's current ratio stands at 5.10, with a quick ratio of 4.88, and a debt-to-equity ratio of 75.51.
Recent Earnings
Neumora Therapeutics is not currently profitable, with a forward P/E ratio not meaningful due to negative earnings. Its latest earnings report showed an EPS of -$1.33. The company is expected to announce its next earnings on August 6, 2026.
Insider Buying and Selling at Neumora Therapeutics, Inc.
Recent insider activity at Neumora Therapeutics includes several purchases. On May 27, 2026, insiders including Fust Matthew, Ho Maykin, Kristina Burow, Alaa Halawa, and David Piacquad each acquired 80,000 shares. These transactions were not part of a planned trading strategy. Additionally, on February 17, 2026, CFO Michael Lee Milligan sold 1,436 shares at an average price of $3.57.
Analysts Set New Price Targets
On June 16, 2026, HC Wainwright & Co. maintained its buy rating with a $7.00 price target for Neumora Therapeutics. Similarly, Needham maintained a buy rating with a target of $5.00. The overall analyst consensus is a buy, with an average target price of $8.91 based on eight analyst opinions.
About Neumora Therapeutics
Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for brain diseases and neuropsychiatric disorders. Headquartered in Watertown, Massachusetts, and led by CEO Dr. Joshua Pinto, the company is advancing several candidates through clinical trials, including navacaprant for major depressive disorder and NMRA-511 for Alzheimer's-related agitation. Neumora aims to address unmet needs in neurodegenerative diseases with innovative therapies.
Bottom Line
HC Wainwright's reaffirmation of its buy rating for Neumora Therapeutics reflects ongoing confidence in the company's pipeline and market potential. As a clinical-stage biotech, Neumora is a subject of interest for investors tracking developments in brain disease treatments. Remember, analyst ratings are forward-looking assessments and may not reflect current market conditions.
See Also
This instant news alert was generated by automated narrative technology and financial data from EarningsIQ and public regulatory filings. It is for informational purposes only and is not financial advice.